Pharmacogenetics of Long-Term Outcomes of Schizophrenia Spectrum Disorders: The Functional Role of CYP2D6 and CYP2C19
Open Access
- 4 September 2023
- journal article
- research article
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 13 (9) , 1354
Abstract
Schizophrenia spectrum disorders (SSD) are complex mental disorders, and while treatment with antipsychotics is important, many patients do not respond or develop serious side effects. Genetic variation has been shown to play a considerable role in determining an individual’s response to antipsychotic medication. However, previous pharmacogenetic (PGx) studies have been limited by small sample sizes, lack of consensus regarding relevant genetic variants, and cross-sectional designs. The current study aimed to investigate the association between PGx variants and long-term clinical outcomes in 691 patients of European ancestry with SSD. Using evidence from the literature on candidate genes involved in antipsychotic pharmacodynamics, we created a polygenic risk score (PRS) to investigate its association with clinical outcomes. We also created PRS using core variants of psychotropic drug metabolism enzymes CYP2D6 and CYP2C19. Furthermore, the CYP2D6 and CYP2C19 functional activity scores were calculated to determine the relationship between metabolism and clinical outcomes. We found no association for PGx PRSs and clinical outcomes; however, an association was found with CYP2D6 activity scores by the traditional method. Higher CYP2D6 metabolism was associated with high positive and high cognitive impairment groups relative to low symptom severity groups. These findings highlight the need to test PGx efficacy with different symptom domains. More evidence is needed before pharmacogenetic variation can contribute to personalized treatment plans.Keywords
Funding Information
- Geestkracht Programme of the Dutch Health Research Council (10-000-1001)
- participating pharmaceutical companies (Lundbeck, AstraZeneca, Eli Lilly, Janssen Cilag) (10-000-1001)
- Amsterdam: Academic Psychiatric Centre of the Academic Medical Center and the mental health institutions: GGZ Ingeest, Arkin, Dijk en Duin, GGZ Rivierduinen, Erasmus Medical Centre, GGZ Noord Holland Noord (10-000-1001)
- Groningen: University Medical Center Groningen and the mental health institutions: Lentis, GGZ Friesland, GGZ Drenthe, Dimence, Mediant, GGNet Warnsveld, Yulius Dordrecht and Parnassia psycho-medical center The Hague (10-000-1001)
- Maastricht: Maastricht University Medical Centre and the mental health institutions: GGzE, GGZ Breburg, GGZ Oost-Brabant, Vincent van Gogh voor Geestelijke Gezondheid, Mondriaan, Virenze riagg, Zuyderland GGZ, MET ggz, Universitair Centrum Sint-Jozef Kort (10-000-1001)
- Utrecht: University Medical Center Utrecht and the mental health institutions Altrecht, GGZ Centraal, and Delta (10-000-1001)
This publication has 59 references indexed in Scilit:
- Schizoaffective Disorder in the DSM-5Schizophrenia Research, 2013
- Genetic Risk and Outcome of Psychosis (GROUP), a multi site longitudinal cohort study focused on gene–environment interaction: objectives, sample characteristics, recruitment and assessment methodsInternational Journal of Methods in Psychiatric Research, 2012
- Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects predictionExpert Opinion on Drug Metabolism & Toxicology, 2010
- The MATRICS Consensus Cognitive Battery, Part 1: Test Selection, Reliability, and ValidityAmerican Journal of Psychiatry, 2008
- The MATRICS Consensus Cognitive Battery, Part 2: Co-Norming and StandardizationAmerican Journal of Psychiatry, 2008
- PLINK: A Tool Set for Whole-Genome Association and Population-Based Linkage AnalysesThe American Journal of Human Genetics, 2007
- Neurocognitive Effects of Antipsychotic Medications in Patients With Chronic Schizophrenia in the CATIE TrialArchives of General Psychiatry, 2007
- Identification of separable cognitive factors in schizophreniaSchizophrenia Research, 2004
- Pharmacogenetic prediction of clozapine responseThe Lancet, 2000
- The Positive and Negative Syndrome Scale (PANSS) for SchizophreniaSchizophrenia Bulletin, 1987